Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program
about
The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations.Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedsideParkinsonian Balance Deficits Quantified Using a Game Industry Board and a Specific Battery of Four Paradigms.Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.Analysis of autonomic modulation of heart rate in patients with Parkinson's disease and elderly individuals submitted to game therapy training.Carbidopa levodopa enteral suspension.What Do Medical Students Know about Deep Brain Stimulation?Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.A clinical view on the development of technology-based tools in managing Parkinson's disease.Algorithms for the treatment of motor problems in Parkinson's disease.The role and structure of the multidisciplinary team in the management of advanced Parkinson's disease with a focus on the use of levodopa-carbidopa intestinal gel.Practical approaches to commencing device-assisted therapies for Parkinson's disease in Australia.Classification of advanced stages of Parkinson's disease: translation into stratified treatments.Intrajejunal levodopa infusion therapy for Parkinson's disease: practical and pragmatic tips for successful maintenance of therapy.Choosing an Advanced Therapy in Parkinson's Disease; is it an Evidence-Based Decision in Current Practice?Wearable Sensors for Advanced Therapy Referral in Parkinson's Disease.Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study.Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed.Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa.Repeated sessions of transcranial direct current stimulation evaluation on fatigue and daytime sleepiness in Parkinson's disease.Changes in Parkinson's disease sleep symptoms and daytime somnolence after bilateral subthalamic deep brain stimulation in Parkinson's disease.Chinese expert consensus on programming deep brain stimulation for patients with Parkinson's disease.Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners
P2860
Q30248922-E5E39DF3-9FD3-4CA9-B14A-9C132418D2D0Q30852749-CB728D61-CB15-426F-AD7C-F456B0BFD449Q37214996-DD2270F1-2FE7-47C3-B974-388084CCAD83Q37698585-DF090A8C-CC2D-4C66-A97A-1C644D614321Q38610810-FA70B3AF-6421-4CAE-B31E-1835E9D27F68Q38643494-C68E2E3D-EA51-400A-9405-A1931B564EE5Q38691961-C13CAEC5-387E-4D07-8410-F2F9452A07FAQ38823793-395A64D6-7652-4342-B936-E2D32F950E83Q38858508-DDC7E4E2-6D0D-41D4-A4A3-B141B8F8FA58Q38992788-749F830F-3C2D-4586-B025-04418F281884Q39099746-3B387AEC-34E4-429F-B02B-C238E6CEA2C9Q39134831-601BA998-C2EC-4DD4-94AF-AB2E6A3E5086Q39200115-59859E64-3883-43DA-A23C-0E75937FBB9DQ39240060-ADDCEDE0-4302-46B3-BC8D-DC123143590DQ39545103-79BB9EB8-E4DB-48F0-8DE0-A6CF8DC4A3ECQ39620234-9CC24342-0739-4545-92FC-DEA8EECC1A82Q47652358-15399759-C696-4E06-8743-22046ED24C29Q47868277-02FAC601-733F-45AF-9AF1-F88D9114858DQ47962428-68CEEBAA-574C-4BF0-9C4B-7ACA8E8D1B0EQ47997995-713F3083-7758-4EAA-9850-865821BEE45AQ48330188-178781EA-812E-4404-910F-6101D222A1CDQ50108912-CFA089AA-3EB7-4E21-9668-EB5E4AC5F53BQ53143036-32A78089-A872-4CDE-8A24-D2469F4E2B89Q53558889-C2978703-92DB-492C-A56E-6A3C3A4E8895Q54968708-982F4550-66A3-4780-8447-0A3D5D727E2CQ55176686-6D686DC4-A535-44EE-82BA-B17B2E772823Q55316973-125AE413-492B-4756-B9E3-1C261264F011Q58571815-BBE721FA-E2D3-4EE4-B37E-44F07146E8E0
P2860
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Collective physician perspecti ...... survey and discussion program
@ast
Collective physician perspecti ...... survey and discussion program
@en
Collective physician perspecti ...... survey and discussion program
@nl
type
label
Collective physician perspecti ...... survey and discussion program
@ast
Collective physician perspecti ...... survey and discussion program
@en
Collective physician perspecti ...... survey and discussion program
@nl
prefLabel
Collective physician perspecti ...... survey and discussion program
@ast
Collective physician perspecti ...... survey and discussion program
@en
Collective physician perspecti ...... survey and discussion program
@nl
P2093
P50
P3181
P1476
Collective physician perspecti ...... survey and discussion program
@en
P2093
J K Krauss
J T Slevin
P Martinez-Martin
R Katzenschlager
T Henriksen
P304
P3181
P356
10.1016/J.PARKRELDIS.2015.07.020
P407
P577
2015-10-01T00:00:00Z